Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Plus CHOEP in Untreated Peripheral T-cell Lymphoma
NCT02987244Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02987244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987244.